Actelion is preparing for transformational growth to benefit all stakeholders, putting processes and infrastructure in place that will take its novel chemical entities currently in late-stage development through to become innovative medicines for patients.
| Date | Event | Description |
| 22 Apr 2010 | Q1 Results 2010 | Actelion reports its first quarter results for 2010 |
| 04 May 2010 | AGM 2010 | Annual General Meeting 2010 – update for stockholders on the progress made in 2009 |
| 20 Jul 2010 | HY Results 2010 | Webcast with financial results for the first 6 months of 2010 |
| 21 Oct 2010 | Q3 Results 2010 | Webcast with financial results for the first 9 months of 2010 |
| In CHF thousands results | Results FY 2009 | Results FY 2008 | in % | |
| Net revenues | 1,772,564 | 1,473,508 | 20 | |
| Operating expenses | 1,433,158 | 1,102,151 | 30 | |
| Operating income | 339,406 | 371,357 | (9) | |
| Cash EBIT | 567,935 | 476,833 | 19 | |
| Net income | 311,270 | 306,073 | 2 | |
| Diluted EPS in CHF | 2.53 | 2.48 | 2 | |
| No of shares in calculation | 122,880 | 123,418 | n/a |
